跨诊断临床分期从童年到成年早期的进展
该前瞻性队列研究基于ALSPAC数据,检验从童年期0期(家族风险)进展至青春期1a期(轻度症状)、再至成年早期1b期(临床显著症状)的可能性,并控制混杂因素。调整混杂后,0期与1a期、1a期与1b期均存在关联,支持临床分期模型的进展假设。
要点
- 童年期0期(家族风险)与青春期1a期(轻度症状)存在独立关联。
- 青春期1a期与成年早期1b期(临床显著症状)存在独立关联。
- 青春期神经质水平介导了1a期至1b期关联的18%。
核心结论
- 符合早期临床分期标准的精神健康问题青年,进展至后续分期的风险升高,且独立于早期生活风险因素。
- 本研究支持精神障碍临床分期模型所依据的进展假设。
研究设计与样本
- 前瞻性队列研究,纳入Avon亲子纵向研究(ALSPAC)中1991至1992年英国Avon地区孕妇及其后代,部分后代随访至成年早期。
- 纳入从出生至24岁提供分期决定因素和潜在混杂因素数据的参与者;数据收集于1991至2015年,分析于2002年1月至2025年6月。
主要发现
- 调整潜在混杂因素后,童年期0期与青春期1a期存在关联(3860名参与者;加权7388名;OR 1.65,95% CI 1.30-2.11)。
- 调整潜在混杂因素后,青春期1a期与成年早期1b期存在关联(1661名参与者;加权7466名;OR 2.07,95% CI 1.07-4.01)。
- 青春期神经质水平介导了青春期1a期与成年早期1b期之间关联的18%。
关键数值与推荐
- 0期标准:一级亲属存在精神分裂症或重度抑郁。
- 1a期标准:12至13岁时存在1至2种抑郁、焦虑或精神病性症状。
- 1b期标准:18至24岁时存在至少中度抑郁、焦虑或精神病性症状并伴功能影响。
- 混杂因素包括出生指定性别、产科风险、父母社会阶层、族裔、家庭逆境、气质、早期生活事件和神经认知,均在童年期测量。
临床怎么用
- 临床可依据家族风险(0期)和青春期轻度症状(1a期)识别进展风险较高的青年。
- 对符合1a期的青少年,可关注神经质水平并评估干预以降低进展至1b期的风险。
局限性
- 研究仅基于ALSPAC队列,结果外推需谨慎。
- 完整数据三个时间点均有的参与者为1375名(加权7342名),存在样本选择与失访可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transdiagnostic clinical staging models for mental disorders are receiving increased attention. However, their underlying assumptions are underresearched; for example, it is not clear whether the observed progression across stages occurs independently of preexisting risk factors. OBJECTIVES: To test the likelihood of progression from stage 0 (familial risk) in childhood to stage 1a (mild symptoms) in adolescence and subsequently to stage 1b (clinically significant symptoms) in young adulthood, accounting for confounders, and to explore potential mediators. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study included participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). ALSPAC included pregnant women and their offspring residing in Avon, United Kingdom, between 1991 and 1992, with a proportion of offspring followed up into young adulthood. Eligible participants provided data on stage determinants and potential confounders from birth until age 24 years. Data were collected from 1991 to 2015 and analyzed from January 2002 to June 2025. EXPOSURES: Exposures were clinical stages 0 and 1a in separate tests of association with stages 1a and 1b, respectively. Criteria for stage 0 were the presence of schizophrenia or severe depression in a first-degree relative. Criteria for stage 1a were the presence of 1 to 2 symptoms of depression, anxiety, or psychosis at ages 12 to 13 years. MAIN OUTCOMES AND MEASURES: Outcomes were stage 1a in adolescence and stage 1b in young adulthood. Criteria for stage 1b were at least moderate symptoms of depression, anxiety, or psychosis, with associated functional impact at ages 18 to 24 years. Confounders were sex assigned at birth, obstetric risk, parental social class, ethnicity, family adversity, temperament, early life events, and neurocognition, measured in childhood. RESULTS: Among those with complete data at all 3 time points (1375 participants; weighted, 7342), 796 participants (57.9%; weighted, 51.5%) were female and 579 (42.1%; weighted, 48.5%) were male. After adjusting for potential confounders, there was an association between stage 0 in childhood and stage 1a in adolescence (3860 participants; weighted, 7388 participants; odds ratio [OR], 1.65, 95% CI, 1.30-2.11) and between stage 1a in adolescence and stage 1b in young adulthood (1661 participants; weighted, 7466 participants; OR, 2.07; 95% CI, 1.07-4.01). Level of neuroticism in adolescence mediated 18% of the association between stage 1a in adolescence and stage 1b in young adulthood. CONCLUSIONS AND RELEVANCE: In this cohort study, young people with mental health problems meeting criteria for early clinical stages were at heightened risk of developing subsequent stages, independent of early life risk factors. This study supports the assumption of progression underlying clinical staging models for mental disorders.
引用
- Ratheesh A, Chen Y, Hammond D, et al. Progression of Transdiagnostic Stages From Childhood to Young Adulthood. JAMA Psychiatry. 2025. PMID: 40991272. doi:10.1001/jamapsychiatry.2025.2648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。